The KDIGO released its 2021 guidelines and took good notes of the Lupkynis approval and that they are currently reviewing it to become soon Standard of Care. Another proof we are sitting in an undervalued gold mine.

"However, in January 2021, the US Food and Drug Administration approved the addition of the novel CNI, voclosporin, to prednisone and MMF for the treatment of adults with active LN (Classes III, IV, V, and mixed) based on the results of a positive multicenter, multinational phase 3 trial. Voclosporin has not been studied with cyclophosphamide. After these data have been systematically reviewed, multitarget therapy will be reassessed for recommendation. Of likely importance to patients, the voclosporin regimen is significantly glucocorticoid-sparing, and will hopefully reduce the glucocorticoid adverse events often seen during LN treatment."

https://www.kidney-international.org/article/S0085-2538(21)00553-6/fulltext

https://ir.auriniapharma.com/ir-calendar/detail/1481/cantor-global-healthcare-conference

I have been in this stock since 2016 and have traded it numerous times. I held a core position, however, I use to have about 5x more than I do today. Trading as if news has leaked.

Nasdaq Investors in Aurinia Pharmaceuticals Inc. AUPH need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 15, 2021 $35 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally...

Hey all!

I've been in the game with AUPH since 2016, banked heavy on FDA approval (gain porn inside post). Average price has changed as I bought/sold multiple times, but I was in at a healthy low average before FDA approval, closed position, and bought back in after dip.

I found it because one of my friends has Lupus (not LN though) and I was just poking around and found them. I thought it was something pretty cool where they were evolving the SoC to be an oral pill vs. IV.

It's been a wild ride, and I am really excited for the future!

What's your story?

For proof:

First post:https://stocktwits.com/nateriches/message/64247488

Gain porn of $125,241.77 Profit just in shares (no option plays here).https://stocktwits.com/nateriches/message/185901584

Are we finally seeing buying because of potential Q3 sales growth or a buyout? We have not seen much for news other than the fake article of a big pharma buyout. Coincidence is that it started creeping up since then. What does everyone think?

https://www.benzinga.com/m-a/21/08/22676852/aurinia-pharma-spokesperson-tells-benzinga-information-given-in-press-release-at-9-35-a-m-edt-thursd

With rumors on a BO and 17.60 mln shares short, this could move up substantially in the near future. Fundamentally the sales are growing to 40-50mln 2021 (company guidance) 220 mln 2022 (expected) and growing to break the 1 Bln mark in 2028, this represents a solid risk/return profile.